A practical reference on gastric juice protein: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-12-21. Anything still debated is marked as such rather than presented as settled.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
| Property | Value | Notes |
|---|---|---|
| Amino acid count | 15 residues | Synthetic pentadecapeptide chain |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Molecular formula | C62H98N16O22 | Free peptide, without counter-ion |
| Theoretical mass | Approximately 1419.5 daltons | Varies slightly with adducts and counter-ions |
| Origin | Fragment of a human gastric juice protein | Source of the BPC designation |
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
== Biosimilar insulin == A biosimilar is a biological medicine that is highly similar to an already approved reference biologic in terms of structure, biological activity, efficacy, and safety. These medicines are large, complex molecules produced through biotechnology in living systems, such as microorganisms, plant cells, or animal cells. Due to differences in the manufacturing process, biosimilars cannot be exact copies of reference biologics but must demonstrate high similarity through extensive structural and functional analysis. Manufacturers are required to show that a biosimilar has no clinically meaningful differences from its reference product regarding safety, purity, and potency, which is assessed through pharmacokinetic (PK) and pharmacodynamic (PD) studies, immunogenicity evaluations, and, if necessary, additional clinical studies. Biosimilars can only be developed and marketed once the patent on the original reference biologic has expired, allowing for competition and increased availability of biologic therapies. The expiration of patents for first-generation insulin analogs has facilitated the development of biosimilar insulins, offering potential to improve global insulin access. Despite the essential role of insulin, approximately half of individuals who require it do not have access due to high costs and limited availability. This issue is particularly pronounced in low-income countries, where economic factors can restrict the use of biologic treatments such as insulin.
=== Homocysteine === Homocysteine, a non-protein amino acid and analogue to the protein amino acid cystine, has been shown to have negative effects on bone health. Higher homocysteine concentrations are likely a result of folate, vitamin B12 B6 deficiencies. In addition, it was found that homocysteine concentration was significantly affected by physical activity. The stimulation of the skeleton through physical activity promotes positive bone remodelling and decreases levels of homocysteine, independently from nutritional intake. Four methods have been proposed regarding the interaction of homocysteine and bone; increase in osteoclast activity, decrease in osteoblast activity, decrease in bone blood flow, and direct action of homocysteine on bone matrix. Homocysteine inhibits lysyl oxidase which is responsible for post-translational modifications of collagen, a key component to bone structure
==== Mechanism of action ==== Ketamine is a mixture of equal amounts of two enantiomers: esketamine and arketamine. Esketamine is a far more potent NMDA receptor pore blocker than arketamine. Pore blocking of the NMDA receptor is responsible for the anesthetic, analgesic, and psychotomimetic effects of ketamine. Blocking of the NMDA receptor results in analgesia by preventing central sensitization in dorsal horn neurons; in other words, ketamine's actions interfere with pain transmission in the spinal cord. The mechanism of action of ketamine in alleviating depression is not well understood, but it is an area of active investigation. Due to the hypothesis that NMDA receptor antagonism underlies the antidepressant effects of ketamine, esketamine was developed as an antidepressant. However, multiple other NMDA receptor antagonists, including memantine, lanicemine, rislenemdaz, rapastinel, and 4-chlorokynurenine, have thus far failed to demonstrate significant effectiveness for depression. Furthermore, animal research indicates that arketamine, the enantiomer with a weaker NMDA receptor antagonism, as well as (2R,6R)-hydroxynorketamine, the metabolite with negligible affinity for the NMDA receptor but potent alpha-7 nicotinic receptor antagonist activity, may have antidepressant action. This furthers the argument that NMDA receptor antagonism may not be primarily responsible for the antidepressant effects of ketamine.
=== Re-creation === Although the wax from the tablets was not preserved, small scratches left on the surface of the wooden tablets allowed for a recreation of the original writing content. These scratches, though perhaps not identifiable with the naked eye, can be visualised and digitally recreated with the assistance of technology. To make the digital recreation of the writing, photographs were taken using different angles of light and thus casting different shadows upon the tablet surface. Once compiled, these pictures gave a view of the surface contours of the tablets, the impressions made in the wood, and thus a look at what was written on the tablet. However, since these tablets were made to be reusable, several overlapping messages may be present on the tablets, making it even more difficult to separate and translate the many messages.
Sources: en.wikipedia.org
An ion-exchange resin or ion-exchange polymer is a resin or polymer that acts as a medium for ion exchange, that is also known as an ionex. It is an insoluble matrix (or support structure) normally in the form of small (0.25–1.43 mm radius) microbeads, usually white or yellowish, fabricated from an organic polymer substrate. The beads are typically porous (with a specific size distribution that will affect its properties), providing a large surface area on and inside them where the trapping of ions occurs along with the accompanying release of other ions, and thus the process is called ion exchange. There are multiple types of ion-exchange resin, that differ in composition if the target is an anion or a cation and are created based on the task they are required for. Most commercial resins are made of polystyrene sulfonate which is followed by polyacrylate.
color standard A liquid solution of known chemical composition and concentration, and hence of known and standardized color, used as a reference in the optical analysis of samples of unknown strength.
== Calculation of Accessible Surface Area == Accessible surface areas is a measure of the solvent exposure of individual atoms or residues (measured in square Angstroms). It corresponds to the surface area of an atom (or residue) that a water molecule can access or touch. In VADAR, the accessible surface areas (ASA) for each residue is presented under two different column headers: RES ASA (residue ASA) and FRAC ASA (fractional ASA). The data listed under the RES ASA column refers to the “residue accessible surface areas” as measured in square Angstroms. The data listed under the FRAC ASA column refers to the fractional residue accessible surface areas (a value ranging from 0 to 1.0). Exposed, exterior, random coil or hydrophilic residues typically have a large fractional accessible surface areas (>0.5), while hydrophobic, beta sheet or interior residues have a small fractional accessible surface areas (<0.2). The fractional accessible surface areas is calculated by dividing a given residue’s observed accessible surface areas by the calculated accessible surface areas for that residue in an extended Gly-Xaa-Gly tripeptide (where Xaa is the residue of interest). VADAR reports accessible surface are values both for the entire amino acid residue and for the amino acid side chains. The accessible surface areas is also calculated for charged atoms (N, O), polar (N, O, S) atoms and for non-polar atoms (C). This information can be used to calculate charged, polar and non-polar surface area.
RBR: 04 × 1.62 Gbit/s = 06.48 Gbit/s bandwidth (data rate of 5.184 Gbit/s or 648 MB/s with 8b/10b encoding) HBR: 04 × 2.70 Gbit/s = 10.80 Gbit/s bandwidth (data rate of 8.64 Gbit/s or 1.08 GB/s) HBR2: 4 × 5.40 Gbit/s = 21.60 Gbit/s bandwidth (data rate of 17.28 Gbit/s or 2.16 GB/s) HBR3: 4 × 8.10 Gbit/s = 32.40 Gbit/s bandwidth (data rate of 25.92 Gbit/s or 3.24 GB/s) UHBR 10: 4 × 10.0 Gbit/s = 40.00 Gbit/s bandwidth (data rate of 38.69 Gbit/s or 4.84 GB/s with 128b/132b encoding and FEC) UHBR 13.5: 4 × 13.5 Gbit/s = 54.00 Gbit/s bandwidth (data rate of 52.22 Gbit/s or 6.52 GB/s) UHBR 20: 4 × 20.0 Gbit/s = 80.00 Gbit/s bandwidth (data rate of 77.37 Gbit/s or 9.69 GB/s) The transmission mode used by the DisplayPort main link is negotiated by the source and sink device (the device accepting the signal) when a connection is made, through a process called Link Training. This process determines the maximum possible speed of the connection. If the quality of the DisplayPort cable is insufficient to reliably handle HBR2 speeds for example, the DisplayPort devices will detect this and switch down to a lower mode to maintain a stable connection. The link can be re-negotiated at any time if a loss of synchronization is detected. Audio data is transmitted across the main link during the video blanking intervals (short pauses between each line and frame of video data).
== Selected articles == Meyer, D. E., & Chilkoti, A. (1999). Purification of recombinant proteins by fusion with thermally-responsive polypeptides. Nature Biotechnology, 17(11), 1112–1115. Nath, N., & Chilkoti, A. (2002). A colorimetric gold nanoparticle sensor to interrogate biomolecular interactions in real time on a surface. Analytical chemistry, 74(3), 504–509. Ma, H., Hyun, J. Chilkoti, A. (2004). "Nonfouling" oligoethylene glycol functionalized polymer brushes synthesized by surface-initiated atom transfer radical polymerization. Advanced Materials, 16, 338–341. Dreher, M. R., Liu, W., Michelich, C. R., Dewhirst, M. W., Yuan, F., & Chilkoti, A. (2006). Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. Journal of the National Cancer Institute, 98(5), 335–344. Ciracì, C., Hill, R. T., Mock, J. J., Urzhumov, Y., Fernández-Domínguez, A. I., Maier, S. A., ... & Smith, D. R. (2012). Probing the ultimate limits of plasmonic enhancement. Science, 337(6098), 1072–1074.
Sources: en.wikipedia.org
The peptide is synthetic, but its sequence matches a segment of a protein present in human gastric juice. It does not occur as a free fifteen-residue peptide in the body.
Rodents account for the large majority of published experiments. Human data are sparse and mostly observational, so cross-species extrapolation remains uncertain.
It is not an approved therapeutic in most jurisdictions. Regulatory status varies by country, and several places restrict it as a research chemical.
It is a chain of fifteen amino acids, referred to as a pentadecapeptide. The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It corresponds to a fragment of a protein found in human gastric juice.